Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma

PURPOSE: The decreased effectiveness of single-agent targeted therapies in advanced non–clear cell renal cell carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study of combination regimens. We evaluated the efficacy of everolimus plus bevacizumab in patients with me...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Voss, Martin H., Molina, Ana M., Chen, Ying-Bei, Woo, Kaitlin M., Chaim, Joshua L., Coskey, Devyn T., Redzematovic, Almedina, Wang, Patricia, Lee, William, Selcuklu, S. Duygu, Lee, Chung-Han, Berger, Michael F., Tickoo, Satish K., Reuter, Victor E., Patil, Sujata, Hsieh, James J., Motzer, Robert J., Feldman, Darren R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2016
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791841/
https://ncbi.nlm.nih.gov/pubmed/27601542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.9084
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller